BriaCell Therapeutics Corp. (TSX: BCT) Presents Phase 3 Data on Biomarker-Driven Approach in Metastatic Breast Cancer
BriaCell Therapeutics Corp., a clinical-stage biotechnology company, has presented new data from its ongoing pivotal Phase 3 trial of Bria-IMT™, an investigational immunotherapy for metastatic breast cancer (MBC). The study, titled BRIA-ABC (NCT06072612), explores how specific biomarkers might predict patient response to the Bria-IMT …
Team Kalkine |
30 Apr 2025| Read Time : 10 Mins